Ipsen S.A. publishes its 2023 Consolidated Financial Statements

Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate

Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline

Ipsen mourns the passing of Henri Beaufour, a founding family Board member

Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue

Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance

Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline

Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III

Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC

Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance